Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06176196 · ClinicalTrials.gov registry record · Phase 2
Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)
A Phase 2 study of Painful Lumbosacral Radiculopathy, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 2
- Development phase
- 218
- Enrollment target
- 20
- Study locations
NCT06176196: Completed Phase 2 study of Painful Lumbosacral Radiculopathy, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06176196 is a Phase 2 study of Painful Lumbosacral Radiculopathy that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 218 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06176196, a Phase 2 study of Painful Lumbosacral Radiculopathy, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 218 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX-548
Study Locations (20)
Florida
- Visionary Investigators Network - Aventura
- Nature Coast Clinical Research - Crystal River - Crystal River
- JY Research Institute - Cutler Bay
- Fleming Island Center for Clinical Research - Fleming Island
- Convenient Medical Research - Hialeah
- Jacksonville Center for Clinical Research - Jacksonville
- L&C Professional Medical Research Institute - Miami
- Medical Research of Westchester - Miami
- ARSN-Brain and Spine Institute - Port Orange
- Accel Research Site - St. Petersburg/Largo - Seminole
California
- Trovare Clinical Research - Bakersfield
- Velocity Clinical Research - Banning - Banning
- Velocity Clinical Research - San Diego - La Mesa
- Probe Clinical Research - Riverside
- Pain Management and Injury Relief - Thousand Oaks
Georgia
- Atlanta Center for Medical Research - Atlanta
- ClinCept Clinical Research - Columbus
- Accel Research Sites - Neurostudies - Decatur
Arizona
- Hope Research Institute - Phoenix
- Arizona Research Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2023-12-13 |
| Est. Completion | 2024-10-16 |
| Phase | Phase 2 |
What the finished NCT06176196 record still lists
NCT06176196 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (64% higher).
The record links to 1 condition, with Painful Lumbosacral Radiculopathy appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06176196 names 20 study sites across 4 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT06176196 about?
NCT06176196 is a clinical study titled "Evaluation of Efficacy and Safety of VX-548 for Painful Lumbosacral Radiculopathy (PLSR)". The purpose of the study is to evaluate the efficacy and safety of VX-548 in treating participants with PLSR.
What is the current status of trial NCT06176196?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 218 participants. The study started on 2023-12-13. Estimated completion is 2024-10-16.
What conditions does trial NCT06176196 study?
This clinical trial studies the following conditions: Painful Lumbosacral Radiculopathy.
What interventions are being tested in trial NCT06176196?
The interventions under investigation include: Placebo (DRUG), VX-548 (DRUG).
Who is sponsoring clinical trial NCT06176196?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06176196 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06176196's enrollment target sits among peer trials
218 284th of 2000 higher than 1,715 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04693858 · 218 participants · NA
Efficacy Trial of the CALM Intervention
- NCT05909202 · 218 participants · NA
A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients
- NCT06000761 · 218 participants · NA
Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit
- NCT06249126 · 218 participants · NA
Primary Subtalar Arthrodesis for Calcaneal Fractures
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI